Posterior fossa ependymoma: current insights
- 9 September 2015
- journal article
- review article
- Published by Springer Nature in Child's Nervous System
- Vol. 31 (10) , 1699-1706
Abstract
Ependymoma is the third most common malignant tumor of the posterior fossa and is a major cause of neurological morbidity and mortality in children. Current treatments, particularly surgery and external beam irradiation result in relatively poor outcomes with significant neurological and cognitive sequelae from treatment. Historical approaches have considered all ependymomas as similar entities based on their morphological appearance.Keywords
This publication has 40 references indexed in Scilit:
- Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cellsActa Neuropathologica, 2014
- Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular studyThe Lancet Oncology, 2013
- Outcome of infants and young children with newly diagnosed ependymoma treated on the “Head Start” III prospective clinical trialJournal of Neuro-Oncology, 2013
- A prognostic gene expression signature in infratentorial ependymomaActa Neuropathologica, 2012
- Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa EpendymomaCancer Cell, 2011
- Salvage chemotherapy for metastatic and recurrent ependymoma of childhoodChild's Nervous System, 2009
- Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective studyThe Lancet Oncology, 2007
- Stem cells of ependymomaBritish Journal of Cancer, 2006
- Radial Glia Serve as Neuronal Progenitors in All Regions of the Central Nervous SystemNeuron, 2004
- Postoperative Chemotherapy Without Irradiation for Ependymoma in Children Under 5 Years of Age: A Multicenter Trial of the French Society of Pediatric OncologyJournal of Clinical Oncology, 2001